Alnylam® Pharmaceuticals
Mar 20, 2025
Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and HealthcareRNA interference (RNAi) therapeutics have garnered significant…
Mar 17, 2025
All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…
Feb 25, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…
Feb 15, 2025
CNBC’s Angelica Peebles talks to Alnylam CEO Yvonne Greenstreet about the new administration, what to expect in 2025 and the latest on their ATTR-Cardiomyopathy…
Jan 23, 2025
Alnylam Pharmaceuticals, Inc., an American company at the forefront of innovation, today received the 2024 Tell Award from Ambassador Niculin Jaeger, Consul General…
Jan 12, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth…
Jun 28, 2023
As part of their continued dedication to raising awareness about hATTR amyloidosis and the impact the disease has on those affected, Alnylam Pharmaceuticals is…
Jan 17, 2019
Hereditary transthyretin-mediated amyloidosis is caused by a mutation in transthyretin (TTR) gene resulting in misfolded TTR protein accumulating as amyloid fibrils…
Jul 04, 2018
Background:
Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.
Methods:
In this phase 3…
Published: Oct 09, 2023
- FDA Cites Insufficient Evidence of Clinical Meaningfulness -
- No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…